"The translation of 'External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification' in simplified Chinese: 腹膜假粘液瘤PSOGI-Ki67分类的外部多中心验证。"
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification.
发表日期：2023 Mar 15
作者：
A Arjona-Sanchez, A Martinez-López, M T Moreno-Montilla, J Mulsow, P Lozano-Lominchar, B Martínez-Torres, B Rau, E Canbay, A Sommariva, M Milione, M Deraco, O Sgarbura, A Torgunrud, V Kapenekian, N J Carr, A Hoorens, J B Delhorme, R Wernert, D Goere, L Martin-Roman, S Cosyns, K Flatmark, B Davidson, L Khellaf, F Pereira-Perez, L Rodriguez-Ortiz, A Ibáñez-Costa, A Romero-Ruiz,
来源：
Cellular & Molecular Immunology
摘要：
腹膜假性黏液瘤（Pseudomyxoma peritonei，PMP）是一种罕见的恶性疾病。将Ki67增殖指数添加到PSOGI PMP分类中，在前期单中心研究中为HG-PMP广泛组提供了两个不同的子类别（HG-PMP≤15%和HG-PMP>15%），生存率也不同。本研究旨在对这一新的分类进行外部和多中心验证。该研究是对历史和国际患者队列样本的前瞻性分析。选择具有较高细胞密度的代表性区域来确定Ki67％。对所有HG-PMP患者进行Ki67增殖指数（％）的测定。使用Cox比例风险模型和多变量Cox模型。使用Kaplan-Meier方法和双尾log-rank检验分析不同PSOGI-Ki67类别对OS和DFS的影响。使用Harrel's C-index和ROC曲线分析其预测准确度。通过保持校准图进行校准。在排除后，有349名患者可供分析。LG-PMP的5年生存率为86％，HG-PMP≤15的生存率为59％，HG-PMP>15的生存率为38％，SRC-PMP的生存率为42％（p = 0.0001）。LG-PMP的5年DFS为49％，HG-PMP≤15的DFS为35％，HG-PMP>15的DFS为16％，SRC-PMP为18％（p = 0.0001）。PSOGI-Ki67的区分能力得到验证。PSOGI-Ki67分类将HG-PMP分类分为两个明确定义的亚类别，可以预测PMP患者的OS和DFS。应该在这些患者的病理报告中常规包含Ki67增殖指数。版权所有©2023 Elsevier Ltd、BASO ~ 癌症外科协会和欧洲外科肿瘤学协会。保留所有权利。
Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ≤15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification.It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan-Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching.After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP≤15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP≤15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated.the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients.Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.